Abstract: The present invention is directed to methods and apparatus for creating a sustained release pathogen vaccine for COVID-19, influenza, HIV and other infectious human and animal viruses and pathogens using supercritical, critical, or near-critical fluids with or without polar cosolvents for simultaneously inactivating virions and pathogens, and encapsulating the inactivated virions and pathogens in biodegradable polymer nanospheres for administration to a patient. The present invention continuously inactivates SARS-CoV-2, influenza, HIV and other infectious human and animal viruses and pathogens, and nanoencapsulates the inactivated virions and pathogens in biodegradable polymer nanospheres to provide a safe and effective sustained-release vaccine, especially for the frail and elderly.

Abstract: This invention is for methods to quantify the inhibition of 5-HT induced contraction of human intestinal smooth muscle and an assay to measure the effects of compounds on nausea, irritable bowel syndrome and irritable bowel disease. This invention can be used to measure the incidence and severity of nausea, and can be used as quality control assay for developing and releasing medications for controlling nausea and emesis.

Abstract: This invention relates to a composition of matter using enhanced gingerols for treating nausea and emesis associated with cancer chemotherapy, pregnancy, elective surgery, radiation therapy, motion sickness, and drug medications, use and schedule of use as well as methods of making. A method of making the enhanced gingerols features supercritical, critical and near-critical fluids with and without polar cosolvents. The capsules include an enhanced extract of ginger rhizome wherein said ginger rhizome has a starting mass and said extract has a 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass and said ratio of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass to starting mass is 90-100%.

Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Abstract: Embodiments of the present invention are directed to dosage forms for treating inflammation and rejection in transplantation injuries, graft versus host disease and stem cell transplants with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof.

Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.

Abstract: This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana (Cannabis) and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and ?9-Tetrahydrocannabinolic Acid (?9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and ?9-Tetrahydrocannabinol (?9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating the Cannabis biomass to convert carboxylic acids prior to extraction and purification.

Abstract: This invention relates to methods for and products from precision manufacturing targeted nanoencapsulated drugs in a microgravity environment utilizing green, environmental-friendly SuperFluids™. Based on these methods, nanoparticles formulation of molecules such as, but not limited to, Bryostatin-1 and other Bryoids, manufactured and lyophilized in a gravity-based environment, will be smaller and more uniform with a higher surface area to volume ratio, approaching ‘picometer dimensions’ in a microgravity environment. Once frozen in Space, these enhanced nanoparticles, ‘picoparticles’ approaching ‘picometer dimensions’ will also find utility on Earth to treat ‘orphan’ and chronic diseases such as cancer, HIV and Alzheimer's disease. The methods feature SuperFluids™ which are supercritical, critical and near-critical fluids with and without polar cosolvents.

Abstract: This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product.

Abstract: Embodiments of the present invention are directed to drug delivery systems, dosage forms and methods for the intranasal administration of Bryostatins for the treatment of neuro-degenerative diseases. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down syndrome and Alzheimer's disease.

Abstract: This invention relates to methods of separating and purifying cannabinoids such as CBD, CBDA, ?9-THC (THC), ?9-THCA (THCA), CBN, CBG and others extracted from Cannabis sativa and other Marijuana biomass. These methods employ the use of segmentation chromatographic purification to establish purities in excess of 98.5%.

Abstract: This invention relates to methods and systems for removing plaque from arteries and blood vessels in human subjects non-invasively utilizing coated superparamagnetic nanoparticles introduced into the human bloodstream and controlled by external magnetic fields to effect plaque removal. Magnetic nanoparticles are injected into a patient, and magnetic fields are used to move the nanoparticles to the site of an arterial blockage. The nanoparticles are then oscillated by means of an alternating current source and oscillating magnetic field. The nanoparticles impact the plaque deposit, causing it to break up, so that it may be safely disintegrated, dissolved in the bloodstream, digested by enzymes or ions and/or removed with the nanoparticles themselves. The nanoparticles are removed by a unipolar magnetic field directing them to be removed at the point of injection or alternative location in the body. The nanoparticles are also removed by natural bodily functions.

Abstract: Method and apparatus for producing a broad-spectrum therapeutic for inactivating multiple coronavirus strains including COVID-19. The present invention generates an in situ light source which can inactivate the coronavirus within the body without damaging host cells. This invention couples chemiluminescence-generating compounds with various light-sensitive anti-viral compounds. When activated by chemiluminescence-generated light, the anti-viral compounds inactivate nearby virus particles. In one aspect, the coupled components are co-encapsulated in polymer nanospheres for oral and intranasal delivery. In another aspect of the invention, the coupled components are co-encapsulated in phospholipid nanosomes for intravenous delivery.

Abstract: Embodiments of the present invention are directed to the administration of co-encapsulated bryostatins and retinoids for the treatment of disease, wherein the co-encapsulated bryostatins and retinoids synergistically increase expression of alpha secretase activity in patients. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and ophthalmic diseases such as glaucoma.

Abstract: The present invention pertains to the nanoencapsulation of siRNA and other biologics in phospholipid nanosomes for the improved delivery of siRNA and other biologics to targeted diseased human or animal organs and human or animal cells and apparatus and methods for making the same. In embodiments of the present invention, novel siRNAs were designed to down regulate CCR5 and CD4, based on an analysis of all known alternative transcripts for each gene from both human and monkey (Macaca mulatta) genomes. Embodiments of the present invention feature supercritical, critical and near critical fluids. Embodiments of the present invention also pertain to down regulation of CXCR4 receptor and targeting of nanosomes containing specific siRNA sequences to cells expressing those receptors on the cell surface by coating them with specific ligands. These include ligands for the receptors CCR5, CD4 and CXCR4.

Abstract: The present invention is directed to methods, kits and compositions for inactivating viral agents in or on articles including blood-based products and feature a light sensitive compound selected from the group consisting of hypericin, pseudohypericin and hypocrellin, a group of light producing compounds comprising luciferase, luciferin, ATP and CDP Star, and emission enhancers or quenchers selected from the group consisting of as Sapphire, Emerald, Ruby, Sapphire-II and Emerald-II.

Abstract: The invention involves the use of supercritical or near supercritical fluids to inactivate pathogens in biologic materials which may or may not be contaminated by pathogens. The pathogen reduced material is then inserted into empty, sterile containment vessels. The apparatus can be used as a means to achieve terminal sterilization of the biologic materials. The preferred method of use for the apparatus includes operation of a conveyor belt to move and fill bottles, flasks, containers, or vials in an assembly line to create the finished product in an effective and timely fashion.

Abstract: The present invention is directed to methods and apparatus for pathogen decontamination of personal protective equipment (PPE), face filtering respiratory devices (FFR) and single use medical devices (SUD) by supercritical fluids, near critical fluids, and critical fluids with or without polar cosolvents. The invention includes a closed processing chamber for containing and processing the PPE, FFR, and SUD by a supercritical fluid, near critical fluid, and critical fluid with or without polar solvents at a specified temperature and pressure for a specified time sufficient to disrupt or inactivate pathogens and viruses on the PPE, FFR, and SUD without damaging the protective equipment so that they may be revitalized for continued use.

Abstract: The novel coronavirus COVID-19 has caused a worldwide pandemic of enormous proportions resulting in significant levels of morbidity and mortality, tremendous pressures on the healthcare system, personal freedoms and society, and an unprecedented impact on the economies of the United States and the world. There are still significant unknowns about this very contagious and deadly virus, and these unknowns are coupled with no natural immunity. A promising therapeutic strategy is the utilization/transfusion of convalescent plasma from recovered COVID-19 patients. There are, however, risks involved in such transfusions from residual virus and other adventitious viruses and bacteria. These risks can be minimized by the pathogen clearance of convalescent plasma units in a hospital setting. There is an immediate need for the rapid pathogen inactivation/clearance of convalescent plasma units from recovered COVID-19 patients.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.